Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Celgene Corporation (CELG) & Agios Pharmaceutical Inc (AGIO): Two Biotech Stock To Watch In ASH Conference

The stage is set for the 56th American Society of Hematology (ASH) conference from Dec 6-9 at San Francisco. Plenty of pharmaceutical and biotech companies will present its data on new progressions in hematology and cancer treatments. Two big bio-tech names that might need some attention from investors are Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceutical Inc (NASDAQ:AGIO). CNBC’s Meg Tirrell and Fast Money Traders, Pete Najarian and Guy Adami talked on CNBC about their picks during the conference.


Tirrell pointed out that a lot of small biotech firms will be moving out of the conference in this year and one of the big names to watch out in the ongoing conference is Celgene Corporation (NASDAQ:CELG). She mentioned that Celgene has been very big in cancer treatment for many years and in 2014, they have partnered with a lot of small biotech and these small biotech companies will be presenting their data in the conference.

Tirrell added that a small biotech name to watch out in the ongoing conference is Agios Pharmaceutical Inc (NASDAQ:AGIO). She mentioned that this company has grown significantly in 2014 with stock prices soaring up by around 350%. She said that in spite of this huge growth people are still rooting for it grow much bigger. She feels that the area of cellular metabolism for cancer treatment which this company is working on is a futuristic technology. She added that Agios Pharmaceutical Inc (NASDAQ:AGIO) will be presenting its data from phase 1 research in the ongoing conference.

Adami feels that Agios Pharmaceutical Inc (NASDAQ:AGIO) is growing too fast for his liking. He pointed at Nov 19, when 4 million AGIO stock traded and there was a huge uptrend in the stock. He was expecting the stock to pull after such a huge uptrend, which happened, but soon after it recovered and grew even faster.

“[…] Huge short interest in this name (AGIO). Its one actually I was probably right but not for long enough period of time if that makes sense. I think it goes higher you know, but I love Celgene still,” Adami said.

Najarian said that he likes Celgene Corporation (NASDAQ:CELG) and he added that he likes other name too, which is Amgen, Inc. (NASDAQ:AMGN).

Disclosure: None

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!